According to a recent study published in the journal Oncogene, a new strategy for treating glioblastoma (GBM) may be blocking an enzyme called PRMT5 in tumor cells. PRMT5, which is shorthand for protein arginine methyltransferase 5, regulates gene transcription and other cell processes.